Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 3 MYR301 trial shows improved health status in chronic hepatitis delta patients treated with bulevirtide, implying its effectiveness.

Patients reported improved health status after treatment with bulevirtide for chronic hepatitis delta.
In a phase 3 trial, those receiving bulevirtide showed significant benefits compared to untreated patients.
The MYR301 trial evaluated patient-reported outcomes and highlighted the treatment's positive impact.
Findings suggest bulevirtide may be a valuable option for managing chronic hepatitis delta, needing further validation.

Buti et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 3 MYR301 trial shows improved health status in chronic hepatitis delta patients treated with bulevirtide, implying its effectiveness.